This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. Primary support for the subproject and the subproject's principal investigator may have been provided by other sources, including other NIH sources. The Total Cost listed for the subproject likely represents the estimated amount of Center infrastructure utilized by the subproject, not direct funding provided by the NCRR grant to the subproject or subproject staff. The use of siRNA for the treatment of various diseases, including cancer and ocular ailments, is a remarkably promising area of research, although new and more efficient delivery methods are still needed. Proposed herein is the development of a new class of chiral polyamines for siRNA complexation and delivery. These polyamines contain several features that are expected to lead to high binding affinities with siRNA, including cationic amines, hydrophobic side chains, and well-defined three-dimensional configurations dictated by the chiral side chains. Moreover, the polyamines contain fluorescent substituents that will allow for the direct imaging of the siRNA-polyamine complexes in cellular environments. The complexation of the polyamines with a model siRNA will be measured using a variety of analytical techniques, and the success of the polyamines in complexing and delivering siRNA will be measured using an in vivo assay with mouse NIH 3T3 cells. The successful transfection of siRNA using these notoriously difficult to transfect cells will demonstrate the advantages of these new polyamines for siRNA complexation and delivery. The siRNA that will be transfected is one targeted against hnRNPA1 expression, which is an RNA-protein complex involved in PKM gene regulation. Aberrant expression of hnRNPA1 has been implicated in a variety of cancers. As such, targeting hnRNPA1 using siRNA will enable the development of new and effective disease treatments.

Agency
National Institute of Health (NIH)
Institute
National Center for Research Resources (NCRR)
Type
Exploratory Grants (P20)
Project #
5P20RR016457-11
Application #
8360095
Study Section
Special Emphasis Panel (ZRR1-RI-4 (01))
Project Start
2011-05-01
Project End
2012-04-30
Budget Start
2011-05-01
Budget End
2012-04-30
Support Year
11
Fiscal Year
2011
Total Cost
$110,831
Indirect Cost
Name
University of Rhode Island
Department
Pharmacology
Type
Schools of Pharmacy
DUNS #
144017188
City
Kingston
State
RI
Country
United States
Zip Code
02881
Hahn, Mark E; Karchner, Sibel I; Merson, Rebeka R (2017) Diversity as Opportunity: Insights from 600 Million Years of AHR Evolution. Curr Opin Toxicol 2:58-71
Preiss, Matthew R; Cournoyer, Eily; Paquin, Karissa L et al. (2017) Tuning the Multifunctionality of Iron Oxide Nanoparticles Using Self-Assembled Mixed Lipid Layers. Bioconjug Chem 28:2729-2736
Taylor, David L; Williamson, Patrick R (2017) Mercury contamination in Southern New England coastal fisheries and dietary habits of recreational anglers and their families: Implications to human health and issuance of consumption advisories. Mar Pollut Bull 114:144-156
Tiwari, Rakesh K; Brown, Alex; Sadeghiani, Neda et al. (2017) Design, Synthesis, and Evaluation of Dasatinib-Amino Acid and Dasatinib-Fatty Acid Conjugates as Protein Tyrosine Kinase Inhibitors. ChemMedChem 12:86-99
Wan, Jerry; Lin, Fuquan; Zhang, Wei et al. (2017) Novel approaches to vitiligo treatment via modulation of mTOR and NF-?B pathways in human skin melanocytes. Int J Biol Sci 13:391-400
Malloy, Thomas E; Kinney, Lorin (2017) Implications for the Self Determine Benevolence and Self-Protection in Intergroup Relations. Self Identity 16:171-193
Vierra, David A; Garzon, Jada L; Rego, Meghan A et al. (2017) Modulation of the Fanconi anemia pathway via chemically induced changes in chromatin structure. Oncotarget 8:76443-76457
Zhang, Jiyong; Klufas, Daniel; Manalo, Karina et al. (2016) HMGB1 Translocation After Ischemia in the Ovine Fetal Brain. J Neuropathol Exp Neurol 75:527-38
Donepudi, Ajay C; Cheng, Qiuqiong; Lu, Zhenqiang James et al. (2016) Hepatic Transporter Expression in Metabolic Syndrome: Phenotype, Serum Metabolic Hormones, and Transcription Factor Expression. Drug Metab Dispos 44:518-26
Ma, Hang; Liu, Weixi; Frost, Leslie et al. (2016) Glucitol-core containing gallotannins inhibit the formation of advanced glycation end-products mediated by their antioxidant potential. Food Funct 7:2213-22

Showing the most recent 10 out of 370 publications